Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, MD, Michael Recht, MD PhD, Nigel S. Key, MD, Frank W.G. Leebeek, MD PhD, Giancarlo Castaman, MD, Susan U. Lattimore, R.N., Paul Van Der Valk, Kathelijne Peerlinck, MD PhD, Michiel Coppens, MD, Niamh O'Connell, MD PhD, John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Peter Kampmann, MD, Karina Meijer, MD PhD, Annette von Drygalski, MD Pharm D, Guy Young, MD, Cedric Hermans, MDMRCP,PhD, Jan Astermark, MD PhD, Robert Klamroth, MD PhD, Richard S. Lemons, MD, Nathan Visweshwar, MD, Shelley Crary, MD MS, Rashid Kazmi, MBBS, Emily Symington, Miguel A. Escobar, MD, Esteban Gomez, MD, Rebecca Kruse-Jarres, MD, Adam Kotowski, MD, Doris Quon, MD PhD, Michael Wang, MD, Allison P. Wheeler, MD, Eileen K Sawyer, PhD, Stephanie Verweij, BSc, Valerie Colletta, MSc, Naghmana Bajma, MD, Robert Gut, MD PhD, Wolfgang A. Miesbach, MD PhD

Blood (2020) 136 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2020-143560

Published: 2020

Journal Articles

Validity of Quantitative Measurements By the Joint Tissue Examination and Damage Exam (JADE) with Musculoskeletal Ultrasound for the Longitudinal Assessment of Hemophilic Arthropathy

Akram Mesleh Shayeb, MD, Richard Barnes, PhD MPH, Nicolas Gallastegui Crestani, MD, Cris Hanacek, BS, Peter Aguero, PT, DPT, Andres Flores, MS, ATC, CES, Rebecca Kruse-Jarres, MD, Bruno Steiner, PT, DPT, LMT, RMSK, Doris Quon, MD PhD, Cindy Bailey, DPT, OCS, SCS, ATC, Annette von Drygalski, MD PharmD, RMSK

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-143133

Published: 2020

Journal Articles

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-137438

Published: 2020

Journal Articles

Risk of Hypertension in Hemophilia Patients with a History of Inhibitors

Anna Ter-Zakarian, Richard Barnes, PhD MPH, Rebecca Kruse-Jarres, MD MPH, Doris Quon, MD PhD, Shannon Jackson, MD FRCPC, Linda Sun, MD, Annette von Drygalski, MD PharmD, RMSK

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136133

Published: 2020

Journal Articles

Pocket Handheld Ultrasound As a Novel Point-of-Care Imaging Modality to Diagnose Bleeding in Hemophilic Joints

Jenny Y Zhou, MD, Katherine C. Rappazzo, Lena Volland, Bruno Steiner, Rebecca Kruse-Jarres, MD MPH, Doris V. Quon, MD PhD, Eric Y. Chang, MD, Annette von Drygalski, MD PharmD

Blood (2016) 128 (22): 2345.

https://doi.org/10.1182/blood.V128.22.2345.2345

Published: 2016

Journal Articles

Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study

Johnny Mahlangu, Johannes Oldenburg, Prof, Michael U Callaghan, MD, Midori Shima, MD PhD, Elena Santagostino, MD PhD, Michaela Lehle, PhD, Marianne Uguen, MSc, Ceri Hirst, PhD, Maggie Moore, RN, Michael Recht, MD PhD, Claudia Garcia, MD, Renchi Yang, MD PhD, Rebecca Kruse-Jarres, MD MPH

Blood (2016) 128 (22): 3800.

https://doi.org/10.1182/blood.V128.22.3800.3800

Published: 2016

Journal Articles

The Hypertension of Hemophilia Is Associated with Vascular Joint Remodeling and Cannot be Explained By the Usual Cardiovascular Risk Factors

Richard FW Barnes, PhD MPH, Thomas J Cramer, PhD, Afrah S Sait, MD, Rebecca Kruse-Jarres, MD MPH, Doris V. Quon, MD PhD, Annette von Drygalski, MD PharmD

Blood (2015) 126 (23): 762.

https://doi.org/10.1182/blood.V126.23.762.762

Published: 2015

Journal Articles

Analysis Of Hemostatic Characteristics using Thromboelastometry in Adults With Sickle Cell Disease and Controls

Maissaa Janbain, MD, Cindy A. Leissinger, MD, Rebecca Kruse-Jarres, MD,MPH

Blood (2013) 122 (21): 4766.

https://doi.org/10.1182/blood.V122.21.4766.4766

Published: 2013

Journal Articles

Treatment Of Serious Bleeds With a B-Domain Deleted Recombinant Porcine Sequence Factor VIII (OBI-1) In Patients With Acquired Hemophilia A: A Prospective Clinical Trial

Rebecca Kruse-Jarres, MD, MPH, Jean St. Louis, MD, Anne Greist, MD, Amy D. Shapiro, MD, Hedy Smith, MD PhD, Pratima Chowdary, MBBS, FRCP, FRCPath, Anja B Drebes, MRCP, FRCPath, Edward D. Gomperts, MD, Miranda Chapman, Min Mo, Aaron Novack, PhD, Heinrich D. Farin, MD

Blood (2013) 122 (21): 206.

https://doi.org/10.1182/blood.V122.21.206.206

Published: 2013

Journal Articles

Natural History Of Inhibitor Recurrence Following Successful Immune Tolerance Induction

Ana G. Antun, MD, Paul Monahan, MD, Marilyn J. Manco-Johnson, MD, Michael Callaghan, MD, Guy Young, MD, Christine Knoll, MD, Shannon Carpenter, MD, MS, Joanna A. Davis, MD, Michael F. Guerrera, MD, Rebecca Kruse-Jarres, MD, MPH, Margaret V. Ragni, MD, MPH, Char Witmer, MD, MSCE, Courtney E. McCracken, PhD, Maralee Kanin, Christine L. Kempton, MD, MSc

Blood (2013) 122 (21): 1106.

https://doi.org/10.1182/blood.V122.21.1106.1106

Published: 2013

Journal Articles

Immune Tolerance Induction (ITI) in Adults with Congenital Hemophilia: A Multicenter Experience

Rebecca Kruse-Jarres, MD/MPH, Maria Elisa Mancuso, MD, PhD, Eva Mingot Castellano, MD, Johnny Mahlangu, MD

Blood (2012) 120 (21): 1123.

https://doi.org/10.1182/blood.V120.21.1123.1123

Published: 2012

Journal Articles

Recombinant B-Domain Deleted Porcine Factor VIII (OBI-1) Safety and Efficacy in the Treatment of Acquired Hemophilia A: Interim Results.

Jean St. Louis, MD, Rebecca Kruse-Jarres, MD/MPH, Anne Greist, MD, Amy D. Shapiro, MD, Hedy Smith, MD PhD, Anja B Drebes, MRCP, FRCPath, Jay N. Lozier, MD, PhD, Edward D. Gomperts, MD

Blood (2012) 120 (21): 2224.

https://doi.org/10.1182/blood.V120.21.2224.2224

Published: 2012

Journal Articles

Phase II Trial of Rituximab in the Treatment of Inhibitors in Congenital Hemophilia A: Results of the RICH Study

Cindy A. Leissinger, MD, Rebecca Kruse-Jarres, MD, Suzanne Granger, MS, Barbara A Konkle, MD, Margaret V. Ragni, MD, MPH, Janna M. Journeycake, MD, Ellis J. Neufeld, MD, PhD, Cassandra Josephson, MD, Carolyn M. Bennett, MD, MS, Leonard A. Valentino, MD, FAAP, Nigel S. Key, MBChB, Leslie Raffini, MD, Marcela Torres, MD, Joan Cox Gill, MD, Susan Assmann, PhD

Blood (2011) 118 (21): 27.

https://doi.org/10.1182/blood.V118.21.27.27

Published: 2011

Journal Articles

Baseline Characteristics Associated with Vitamin D Deficiency in Sickle Cell Disease and the Effect of Vitamin D Replacement

Soyoung Park, Rebecca Kruse-Jarres, MD, Davis Ogitani

Blood (2011) 118 (21): 2139.

https://doi.org/10.1182/blood.V118.21.2139.2139

Published: 2011

Journal Articles

Vitamin D Deficiency In Pediatric Patients with Sickle Cell Disease Correlates with Reticulocytosis but Not with Clinical Disease Severity

Amanda C Winters, Rebecca Kruse-Jarres, MD, MPH, Julie Kanter, MD

Blood (2010) 116 (21): 4820.

https://doi.org/10.1182/blood.V116.21.4820.4820

Published: 2010

Journal Articles

Objective Markers to Evaluate Pain in Sickle Cell Disease

Nnenaya Agochukwu, Rebecca Kruse-Jarres, MD

Blood (2008) 112 (11): 4713.

https://doi.org/10.1182/blood.V112.11.4713.4713

Published: 2008

Journal Articles

The Role of Race and Ethnicity in the Clinical Outcomes of Severe Hemophilia A Patients with Inhibitors.

Rebecca Kruse-Jarres, MD, MPH, Nick M. Pajewski, Cindy A. Leissinger, MD

Blood (2007) 110 (11): 1163.

https://doi.org/10.1182/blood.V110.11.1163.1163

Published: 2007

Journal Articles

DDAVP Versus vWF-Containing Factor Concentrate in a Patient with ET Associated Acquired von Willebrand Syndrome (AVWS).

Rebecca Kruse-Jarres, MD, MPH, Cindy A. Leissinger, MD

Blood (2006) 108 (11): 4053.

https://doi.org/10.1182/blood.V108.11.4053.4053

Published: 2006

NARROW

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Validity of Quantitative Measurements By the Joint Tissue Examination and Damage Exam (JADE) with Musculoskeletal Ultrasound for the Longitudinal Assessment of Hemophilic Arthropathy

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Risk of Hypertension in Hemophilia Patients with a History of Inhibitors

Pocket Handheld Ultrasound As a Novel Point-of-Care Imaging Modality to Diagnose Bleeding in Hemophilic Joints

Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study

The Hypertension of Hemophilia Is Associated with Vascular Joint Remodeling and Cannot be Explained By the Usual Cardiovascular Risk Factors

Analysis Of Hemostatic Characteristics using Thromboelastometry in Adults With Sickle Cell Disease and Controls

Treatment Of Serious Bleeds With a B-Domain Deleted Recombinant Porcine Sequence Factor VIII (OBI-1) In Patients With Acquired Hemophilia A: A Prospective Clinical Trial

Natural History Of Inhibitor Recurrence Following Successful Immune Tolerance Induction

Immune Tolerance Induction (ITI) in Adults with Congenital Hemophilia: A Multicenter Experience

Recombinant B-Domain Deleted Porcine Factor VIII (OBI-1) Safety and Efficacy in the Treatment of Acquired Hemophilia A: Interim Results.

Phase II Trial of Rituximab in the Treatment of Inhibitors in Congenital Hemophilia A: Results of the RICH Study

Baseline Characteristics Associated with Vitamin D Deficiency in Sickle Cell Disease and the Effect of Vitamin D Replacement

Vitamin D Deficiency In Pediatric Patients with Sickle Cell Disease Correlates with Reticulocytosis but Not with Clinical Disease Severity

Objective Markers to Evaluate Pain in Sickle Cell Disease

The Role of Race and Ethnicity in the Clinical Outcomes of Severe Hemophilia A Patients with Inhibitors.

DDAVP Versus vWF-Containing Factor Concentrate in a Patient with ET Associated Acquired von Willebrand Syndrome (AVWS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only